Core Insights - C4 Therapeutics, Inc. presented promising Phase 1 clinical trial data for cemsidomide, an IKZF1/3 degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma, showing a 50% overall response rate (ORR) at the highest dose level of 100 µg and a 40% ORR at the 75 µg dose level [1][2][10] Phase 1 Trial Results - The trial included 72 heavily pretreated patients, with a median of seven prior therapies, and demonstrated a median duration of response of 9.3 months [6][11] - Cemsidomide achieved over 50% degradation of IKZF1 and over 80% degradation of IKZF3, indicating strong pharmacodynamic effects [11][8] - Safety profile was favorable, with low rates of treatment-related adverse events and no discontinuations related to cemsidomide [7][11] Development Strategy - C4T plans to initiate a Phase 2 single-arm registrational trial in Q1 2026 and a Phase 1b trial in Q2 2026, both aimed at evaluating cemsidomide in combination with dexamethasone and a BCMA BiTE, respectively [12][13][16] - The company aims for accelerated approval pathways based on the promising safety and efficacy data [10][12] Market Context - Multiple myeloma remains an incurable disease, with a significant need for new therapeutic options, especially for patients who have progressed on existing treatments [17][4] - Cemsidomide is positioned as a potential class-leading treatment option due to its differentiated safety and efficacy profile, particularly in heavily pretreated patient populations [3][4][5]